Union européenne - bulgare - EMA (European Medicines Agency)

sanofi winthrop industrie - isatuximab - Множествена миелома - Антинеопластични средства - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.

Union européenne - bulgare - EMA (European Medicines Agency)

hansa biopharma ab - imlifidase - desensitization, immunologic; kidney transplantation - Имуносупресори - idefirix is indicated for desensitisation treatment of highly sensitised adult kidney transplant patients with positive crossmatch against an available deceased donor. the use of idefirix should be reserved for patients unlikely to be transplanted under the available kidney allocation system including prioritisation programmes for highly sensitised patients.

Union européenne - bulgare - EMA (European Medicines Agency)

astrazeneca ab - chadox1-sars-cov-2 - covid-19 virus infection - Ваксини - vaxzevria is indicated for active immunisation to prevent covid 19 caused by sars cov 2, in individuals 18 years of age and older. Използването на тази ваксина трябва да бъде приложена в съответствие с официалните препоръки.

Union européenne - bulgare - EMA (European Medicines Agency)

pierre fabre medicament - tabelecleucel - lymphoproliferative disorders - ebvallo is indicated as monotherapy for treatment of adult and paediatric patients 2 years of age and older with relapsed or refractory epstein-barr virus positive post-transplant lymphoproliferative disease (ebv+ ptld) who have received at least one prior therapy. for solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate.

Union européenne - bulgare - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - carcinoma, hepatocellular - Антинеопластични средства - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Bulgarie - bulgare - БАБХ (Българска агенция по безопасност на храните)

ВЕТПРОМ АД - ivermectin; closantel - инжекционен разтвор - 5 mg/ml; 125 mg/ml - говеда

Bulgarie - bulgare - БАБХ (Българска агенция по безопасност на храните)

chanelle pharmaceuticals manufacturing ltd - фипронил; (с)-метопрен - разтвор за прилагане върху ограничен участък - 134,00 mg; 120,60mg - кучета

Bulgarie - bulgare - БАБХ (Българска агенция по безопасност на храните)

chanelle pharmaceuticals manufacturing ltd - фипронил; (с)-метопрен - разтвор за прилагане върху ограничен участък - 268,00mg; 241,20mg - кучета

Bulgarie - bulgare - БАБХ (Българска агенция по безопасност на храните)

chanelle pharmaceuticals manufacturing ltd - фипронил; (с)-метопрен - разтвор за прилагане върху ограничен участък - 402mg; 368,80mg - кучета

Bulgarie - bulgare - БАБХ (Българска агенция по безопасност на храните)

chanelle pharmaceuticals manufacturing ltd. - фипронил; (с)-метопрен - разтвор за прилагане върху ограничен участък - 50mg; 60mg - котки, порове